Annexon, Inc. (ANNX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Annexon, Inc. (ANNX)
Go deeper and ask any question about ANNX
Company Performance
Current Price
as of Sep 13, 2024$7.20
P/E Ratio
N/A
Market Cap
$760.71M
Description
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Metrics
Overview
- HQBrisbane, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerANNX
- Price$7.2+6.98%
Trading Information
- Market Cap$760.71M
- Float79.48%
- Average Daily Volume (1m)932,573
- Average Daily Volume (3m)1,396,200
- EPS-$1.22
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$29.61M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$32.72M
- EV$299.16M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account
Factset